Basic Information
RNALocate ID: | RLID:11001262 |
RNA Symbol: | hsa-miR-196a-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-196a |
RNA ID: | miRBase:MIMAT0000226 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20615901 |
Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
Method: | Microarray|RT-PCR |
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001548 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001549 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001550 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001551 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001552 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001553 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001257 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
RLID:11001258 | Exosome | Serum | 18589210 |
RLID:11001259 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11001260 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11001261 | Exosome | Brain tissue | 23382797 |
RLID:11001263 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000037 | Exosome | Colon tissue|Tongue tissue | |
RLID-D:11000305 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-196a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-23970 |
MNDR | hsa-miR-196a-5p | Oral squamous cell carcinoma | MNDR-E-MI-23971 |
MNDR | hsa-miR-196a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-23972 |
MNDR | hsa-miR-196a-5p | Follicular cleaved lymphoma | MNDR-E-MI-23973 |
MNDR | hsa-miR-196a-5p | Lymphoma | MNDR-E-MI-23974 |
MNDR | hsa-miR-196a-5p | Non-hodgkin lymphoma | MNDR-E-MI-23975 |
MNDR | hsa-miR-196a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-23976 |
MNDR | hsa-miR-196a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-23977 |
MNDR | hsa-miR-196a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-23978 |
MNDR | hsa-miR-196a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-23979 |
MNDR | hsa-miR-196a-5p | Breast cancer luminal | MNDR-E-MI-23980 |
MNDR | hsa-miR-196a-5p | Niemann-pick disease type c | MNDR-E-MI-23981 |
MNDR | hsa-miR-196a-5p | Small intestine cancer | MNDR-E-MI-23982 |
MNDR | hsa-miR-196a-5p | Prostate cancer | MNDR-E-MI-23983 |
MNDR | hsa-miR-196a-5p | Chronic lymphocytic leukemia | MNDR-E-MI-23984 |
MNDR | hsa-miR-196a-5p | Gastric cancer | MNDR-E-MI-23985 |
MNDR | hsa-miR-196a-5p | Adrenoleukodystrophy | MNDR-E-MI-23986 |
MNDR | hsa-miR-196a-5p | Intracranial aneurysm | MNDR-E-MI-23987 |
MNDR | hsa-miR-196a-5p | Esophageal carcinoma | MNDR-E-MI-23988 |
MNDR | hsa-miR-196a-5p | Heart disease | MNDR-E-MI-23989 |
MNDR | hsa-miR-196a-5p | Head and neck cancer | MNDR-E-MI-23990 |
MNDR | hsa-miR-196a-5p | Vitiligo | MNDR-E-MI-23991 |
MNDR | hsa-miR-196a-5p | Leukemia | MNDR-E-MI-23992 |
MNDR | hsa-miR-196a-5p | Acute leukemia | MNDR-E-MI-23993 |
MNDR | hsa-miR-196a-5p | Huntington disease | MNDR-E-MI-23994 |
MNDR | hsa-miR-196a-5p | Chorea | MNDR-E-MI-23995 |
MNDR | hsa-miR-196a-5p | Lung cancer | MNDR-E-MI-23996 |
MNDR | hsa-miR-196a-5p | Down syndrome | MNDR-E-MI-23997 |
MNDR | hsa-miR-196a-5p | Parkinson disease | MNDR-E-MI-23998 |
MNDR | hsa-miR-196a-5p | Niemann-pick disease | MNDR-E-MI-23999 |
MNDR | hsa-miR-196a-5p | Breast cancer | MNDR-E-MI-24000 |
MNDR | hsa-miR-196a-5p | Congenital heart disease | MNDR-E-MI-24001 |
MNDR | hsa-miR-196a-5p | Neuroendocrine neoplasia | MNDR-E-MI-24002 |
MNDR | hsa-miR-196a-5p | Pancreatic cancer | MNDR-E-MI-24003 |
MNDR | hsa-miR-196a-5p | Pancreatic endocrine carcinoma | MNDR-E-MI-24004 |
MNDR | hsa-miR-196a-5p | Malignant melanoma | MNDR-E-MI-24005 |
MNDR | hsa-miR-196a-5p | Rectum adenocarcinoma | MNDR-E-MI-24006 |
MNDR | hsa-miR-196a-5p | Colon cancer | MNDR-E-MI-24007 |
MNDR | hsa-miR-196a-5p | Colon adenocarcinoma | MNDR-E-MI-24008 |
MNDR | hsa-miR-196a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-24009 |
MNDR | hsa-miR-196a-5p | Familial ovarian cancer | MNDR-E-MI-24010 |
MNDR | hsa-miR-196a-5p | Prostate adenocarcinoma | MNDR-E-MI-24011 |
MNDR | hsa-miR-196a-5p | Endometriosis | MNDR-E-MI-24012 |
MNDR | hsa-miR-196a-5p | Pulmonary tuberculosis | MNDR-E-MI-24013 |
MNDR | hsa-miR-196a-5p | Carcinoma ductal breast | MNDR-E-MI-24014 |
MNDR | hsa-miR-196a-5p | Glioblastoma | MNDR-E-MI-24015 |
MNDR | hsa-miR-196a-5p | Glioma | MNDR-E-MI-24016 |
MNDR | hsa-miR-196a-5p | Osteosarcoma | MNDR-E-MI-24017 |
MNDR | hsa-miR-196a-5p | Breast carcinoma | MNDR-E-MI-24018 |
MNDR | hsa-miR-196a-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-24019 |
MNDR | hsa-miR-196a-5p | Uterus cancer | MNDR-E-MI-24020 |
MNDR | hsa-miR-196a-5p | Gastric adenocarcinoma | MNDR-E-MI-24021 |
MNDR | hsa-miR-196a-5p | Pituitary adenoma | MNDR-E-MI-24022 |
MNDR | hsa-miR-196a-5p | Lung squamous cell carcinoma | MNDR-E-MI-24023 |
MNDR | hsa-miR-196a-5p | Non-small cell lung cancer | MNDR-E-MI-24024 |
MNDR | hsa-miR-196a-5p | Lung adenocarcinoma | MNDR-E-MI-24025 |
MNDR | hsa-miR-196a-5p | Adrenocortical carcinoma | MNDR-E-MI-24026 |
MNDR | hsa-miR-196a-5p | Thyroid carcinoma | MNDR-E-MI-24027 |
MNDR | hsa-miR-196a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-24028 |
MNDR | hsa-miR-196a-5p | Scleroderma | MNDR-E-MI-24029 |
MNDR | hsa-miR-196a-5p | Carcinoma renal cell | MNDR-E-MI-24030 |
MNDR | hsa-miR-196a-5p | Renal clear cell carcinoma | MNDR-E-MI-24031 |
MNDR | hsa-miR-196a-5p | Biliary tract cancer | MNDR-E-MI-24032 |
MNDR | hsa-miR-196a-5p | Esophageal adenocarcinoma | MNDR-E-MI-24033 |
MNDR | hsa-miR-196a-5p | Cholangiocarcinoma | MNDR-E-MI-24034 |
MNDR | hsa-miR-196a-5p | Esophageal cancer | MNDR-E-MI-24035 |
MNDR | hsa-miR-196a-5p | Infertility | MNDR-E-MI-24036 |
MNDR | hsa-miR-196a-5p | Lung small cell carcinoma | MNDR-E-MI-24037 |
MNDR | hsa-miR-196a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-24038 |
MNDR | hsa-miR-196a-5p | Testicular germ cell cancer | MNDR-E-MI-24039 |
MNDR | hsa-miR-196a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-24040 |
MNDR | hsa-miR-196a-5p | Breast invasive carcinoma | MNDR-E-MI-24041 |
MNDR | hsa-miR-196a-5p | Hepatocellular carcinoma | MNDR-E-MI-24042 |
MNDR | hsa-miR-196a-5p | Embryonal cancer | MNDR-E-MI-24043 |
MNDR | hsa-miR-196a-5p | Familiar ovarian carcinoma | MNDR-E-MI-24044 |
MNDR | hsa-miR-196a-5p | B-cell lymphoma | MNDR-E-MI-24045 |
MNDR | hsa-miR-196a-5p | Retinoblastoma | MNDR-E-MI-24046 |
MNDR | hsa-miR-196a-5p | Barrett's adenocarcinoma | MNDR-E-MI-24047 |
MNDR | hsa-miR-196a-5p | Hodgkin lymphoma | MNDR-E-MI-24048 |
MNDR | hsa-miR-196a-5p | Mouth neoplasms | MNDR-E-MI-24049 |
MNDR | hsa-miR-196a-5p | Crohn disease | MNDR-E-MI-24050 |
MNDR | hsa-miR-196a-5p | Tonsil cancer | MNDR-E-MI-24051 |
MNDR | hsa-miR-196a-5p | Neuromyelitis optica | MNDR-E-MI-24052 |
MNDR | hsa-miR-196a-5p | Gastrointestinal stromal tumor | MNDR-E-MI-24053 |
MNDR | hsa-miR-196a-5p | Colorectal cancer | MNDR-E-MI-24054 |
MNDR | hsa-miR-196a-5p | Type 2 diabetes mellitus | MNDR-E-MI-24055 |
MNDR | hsa-miR-196a-5p | Multiple myeloma | MNDR-E-MI-24056 |
MNDR | hsa-miR-196a-5p | Ependymoma | MNDR-E-MI-24057 |
MNDR | hsa-miR-196a-5p | Prostatic neoplasms | MNDR-E-MI-24058 |
MNDR | hsa-miR-196a-5p | Hypersomnolence idiopathic | MNDR-E-MI-24059 |
MNDR | hsa-miR-196a-5p | Stroke | MNDR-E-MI-24060 |
MNDR | hsa-miR-196a-5p | Stroke lacunar | MNDR-E-MI-24061 |
MNDR | hsa-miR-196a-5p | Barrett's carcinogenesis | MNDR-E-MI-24062 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ANXA1 | Homo sapiens | RR00084307 |
TOP